Phenotypic changes in mouse leukemia L1210 cells with alterations in the effector-binding subunit of ribonucleotide reductase

Advances in Enzyme Regulation

Volumn 40, Issue 1, 2000, Pages 3-15

  Cory, Joseph G ^a   Somerville, Lilla ^a   He, Ai Wu Ruth ^a   Cory, Ann H ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYADENOSINE; DOXORUBICIN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN P53; PROTEIN SYNTHESIS INHIBITOR; RIBONUCLEOTIDE REDUCTASE; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL; ANIMAL CELL; APOPTOSIS; BINDING SITE; CELL CYCLE; CELL LINE; CHEMISTRY; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME INHIBITION; ENZYME SUBUNIT; ENZYMOLOGY; GENETICS; LEUKEMIA CELL; LEUKEMIA L 1210; METABOLISM; MOUSE; NONHUMAN; PATHOLOGY; PHENOTYPE; PROTEIN SYNTHESIS INHIBITION;

ANIMALIA;

EID: 0034083393     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2571(99)00025-4     Document Type: Conference Paper

References (38)

1. J. G. CORY, Role of ribonucleotide reductase in cell division, pp. 1-16 inc. Inhibitors of Ribonucleoside Diphosphate Reductase, International Encyclopedia of Pharmacology and Therapeutics, Section 28. (J. G. CORY and A. H. CORY, eds.) Pergamon Press New York. (1998).
2. H. L. ELFORD, M. FREESE, E. PASSAMANI and H. P. MORRIS, Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas, J. Biol. Chem. 245, 5228-5233 (1970).
3. E. TAKEDA and G. WEBER, Role of ribonucleotide reductase in expression of the neoplastic program, Life Sci. 28, 1007-1014 (1981).
4. I. W. CARAS and D. W. MARTIN JR, Molecular cloning of the cDNA for a mutant mouse ribonucleotide reductase M1 that produces a dominant muta tor phenotype in mammalian cells, Mol. Cell Biol. 8, 2698-2704 (1988).
5. L. THELANDER and P. BERG, Isolation and characterization of expressible cDNA clones encoding the Ml and M2 subunits of mouse ribonucleotide reductase, Mol. Cell Biol. 6, 3433-3442 (1986).
6. J. G. CORY and A. E. FLEISCHER, Specific inhibitors directed at the individual components of ribonucleotide reductase as an approach to combination chemotherapy, Cancer Res. 39, 4600-4604 (1979).
7. A. SATO, G. L. CARTER, P. E. BACON and J. G. CORY, Effects of combination of drugs having different modes of action at the ribonucleotide reductase site on the growth of L1210 cells in culture, Cancer Res. 42, 4353-4357 (1982).
8. J. G. CORY and G. L. CARTER, Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors, Cancer Res. 48, 839-843 (1988).
9. G. L. CARTER and J. G. CORY, Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells, Cancer Res. 48, 5796-5799 (1988).
10. A. H. CORY, A. SATO, D. P. THOMPSON and J. G. CORY, Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitors 4-methyl-5-amino-1-formylisoquinoline thisosemicarbazone, Oncology Res. 8, 449-456 (1996).
11. G. L. CARTER and J. G. CORY, Selective resistance of L1210 cell lines to inhibitors directed at the subunits of ribonucleotide reductase, Advan. Enzyme Regul. 29, 123-139 (1989).
12. J. G. CORY, A. H. CORY, S. D. LONG, G. L. CARTER and C. E. JOHNSON, Altered steady-state levels of the messenger RNAs for c-myc and p-53 in L1210 cell lines resistant to deoxyadenosine, Cancer Res. 52, 2000-2003 (1992).
13. J. G. CORY, A-W.R. HE and A. H. CORY, Deoxyadenosine-resistant mouse leukemia L1210 cell line with alterations in early response genes and p53, Anticancer Res. 16, 3483-3490 (1996).
14. J. G. CORY, A. H. CORY, A. LORICO, G. RAPPA and A. C. SATORELLI, Altered efflux of mouse leukemia L1210 cells resistant to 4-methyl-5-amino-1-formylisoquinoline thisosemicarbazone, Anticancer Res. 17, 3185-3194 (1997).
15. A. H. CORY, A-W.R. HE and J. G. CORY, Multifactorial mechanisms of drug resistance in tumor cell populations selected for resistance to specific chemotherapeutic agents, Advan. Enzyme Regul. 38, 3-18 (1998).
16. D. P. THOMPSON, G. L. CARTER and J. G. CORY, Changes in the messenger RNA levels for the subunits of ribonucleotide reductase during the cell cycle of leukemia L1210 cells, Cancer Commun. 1, 253-260 (1989).
17. A-W.R. HE and J. G. CORY, Effect of ionizing radiation on wild-type and mutant mouse leukemia L1210 cells, Oncology Res. 10, 455-464 (1998).
18. Y. YIN, M. A. TAINSKY, F. Z. BISCHOFF, L. C. STRONG and G. M. WAHL, Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant alleles, Cell 70, 937-948 (1992).
19. L. R. LIVINGSTONE, A. WHITE, J. SPROUSE, E. LIVANOS, T. JACKS and T. D. TLSTY, Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53, Cell 70, 923-935 (1992).
20. S. W. LOWE, H. E. RULEY, T. JACKS and D. E. HOUSEMAN, p-53 dependent apoptosis modulates the cytotoxicity of anticancer agents, Cell 74, 957-967 (1993).
21. J. L. SHERLEY, Guanine nucleotide biosynthesis is regulated by the cellular p53 concentration, J. Biol. Chem. 266, 24,815-24,828 (1991).
22. A. H. CORY and J. G. CORY, Cellular response in mouse leukemia cells made resistant to deoxyadenosine, Biochem. Biophys. Res. Commun. 249, 687-691 (1998).
23. L. H. HARTWELL and T. A. WEINERT, Checkpoints: Controls that ensure the order of the cell cycle events, Science 246, 629-634 (1989).
24. M. B. KASTAN, O. ONYEKWERE, D. SIDRANDKY, B. VOGELSTEIN and R. W. CRAIG, Participation of p53 protein in cellular response to DNA damage, Cancer Res. 51, 6304-6311 (1991).
25. A-W.R. HE and J. G. CORY, Effect of doxorubicin on wild-type and deoxyadenosine-resistant mouse leukemia L1210 cells, Int. J. Oncology 14, 891-895 (1999).
26. J. J. MAIO, G. L. GRAHAM and F. L. BROWN, Induction of G2 arrest and gene expression by 2-aminopurine in human U937 promonocyte-macrophage cells, Exp. Cell Res. 219, 442-448 (1995).
27. S. T. PALAYOOR, R. M. MACKLIS, E. A. BUMP and C. N. COLEMAN, Modulation of radiation-induced apoptosis and G2/M block in murine T-lymphoma cells, Radiation Res. 141, 235-243 (1995).
28. L. SOMERVILLE and J. G. CORY, Altered sensitivity of deoxyadenosine-resistant mouse leukemia L1210 cells to various kinase inhibitors, Anticancer Res. 19, 1021-1026 (1999).
29. A. ARCARO and M. P. WYMANN, Wortmannin is a potent phosphatidylinositol-3-kinase inhibitor: the role of phosphorinositol 3,4,5-triphosphate in neutrophil response, Biochem. J. 296, 297-301 (1993).
30. D. T. DUDLEY, P. LONG, S. J. DECKER, J. B. ALEXANDER and A. R. SALTIEL, A synthetic inhibitor of the mitogen-activated protein kinase cascade, Proc. Natl. Acad. Sci. USA 92, 7686-7689 (1995).
31. D. R. ALESSI, A. CUENDA, C. PHILIP, D. T. DUDLEY and A. R. SALTIEL, PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase in vitro and in vivo, J. Biol. Chem. 270, 27,489-27,494 (1995).
32. L. SOMERVILLE and J. G. CORY, UCN-01 enhances roscovitine-induced apoptosis in deoxyadenosine-resistant mouse leukemia L1210 cells, Proc. Am. Assoc. Cancer Res. 40, 11 (1999).
33. R-G. SHAO, C-X. CAO, T. SHIMIZA, P. M. O'CONNOR, K. W. KOHN and Y. POMMIES, Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function, Cancer Res. 57, 4029-4035 (1997).
34. A-W.R. HE and J. G. CORY, p53-Independent anisomycin induced G1 arrest and apoptosis in L1210 cell lines, Anticancer Res. 19, 421-428 (1999).
35. E. CAUCO, C. A. HAZALIN and L. C. MAHADEVAN, Anisomycin-activated protein kinase p45 and p55 but not mitogen-activated protein kinase ERK-1 and -2 are implicated in the induction of c-fos and c-jun, Mol. Cell Biol. 14, 7352-7362 (1994).
36. D. R. EDWARDS and L. C. MAHADEVAN, Protein synthesis inhibitors differentially superinduce c-fos and c-jun by three distinct mechanisms: lack of evidence for labile repressors, EMBO J. 11, 2415-2424 (1992).
37. S. P. LINKS, K. C. CLARKIN, A. DILEONARDO, A. TSON and G. M. WAHL, A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage, Genes Develop. 10, 934-947 (1996).
38. W. R. TAYLOR, M. L. AGARWAL, A. AGARWAL, D. W. STACEY and G. R. STARK, p53 inhibits entry into mitosis when DNA synthesis is blocked, Oncogene 18, 283-295 (1999).